Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly Send to Friend Enquire before Buying Electronic   Melanoma Therapeutics: Which Strategy Will Take Us There? Bioseeker, July 2005   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells. An example of this approach is the novel antisense oligonucleotide Genasense® that targets the antiapoptotic gene bcl-2. Recently, Genta initiated a European regulatory submission for Genasense® plus chemotherapy for patients with advanced melanoma by sending a letter of intent to EMEA for Marketing Authorization Application. This in-depth analysis, 200+ pages and almost 100 figures, tables and boxes, deals with the current therapy strategies employed and opportunities for increased pharmaceutical intervention, in the context of the present competitive landscape for malignant melanoma. This report covers the latest on: - Disease overview, including incidence, unmet needs, risk factors, screening and diagnosis. - Analysis of current treatment and key therapeutic strategies, including surgery, immunotherapy, vaccines and combination therapies. - Includes product profiles of key drugs by class. - Progress analysis on more than 60 pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors. - Competitive landscape analysis, including extensive lay-out of competitors with collaborations, licensing, M&A etc, major highlights, trends and company profiles on more than 50 of the most important companies in melanoma. Example of candidate drugs included: AP 12009, BAY 504798, Bevacizumab, CANVAXIN, CP 4055, DISC-GMCSF, Endostatin, HSPPC 96, Iboctadekin, INO 1001, MEL-VAC, MTI 506, MTI SAM3, MX 128495, Oblimersen, ONCOFLU, OncoVax, OncoVEX GM-CSF, Peginterferon alfa-2b, PI 88, SGN 17/19, TC 101C, TG 1041, TRANSVAX, UVIDEM, VITAXIN MAb and many more. Customers who bought this item also bought The Global Structure of Melanoma R&D Strategic Perspectives: Malignant Melanoma - Biotechnology-Driven Agents Finding a Flagship Indication? Metabolic Syndrome: New Opportunities in Diagnostics and Therapeutics Late Stage Deals: Strategy, Structure and Payment Terms Stakeholder Opinions: Malignant Melanoma - High Hurdles, High Rewards, Are Vaccines Only Skin Deep? Niche Cancers 2001: Melanoma Prime Therapeutics Business Intelligence Report Cancer Therapy Worldwide Market Survey: Analysis and Forecast - Technology, Sales and Company Profiles

		Top of page

All rights reserved. Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster